WO2019212427A3 - Compositions comprenant de l'erdostéine et de l'acide ascorbique - Google Patents

Compositions comprenant de l'erdostéine et de l'acide ascorbique Download PDF

Info

Publication number
WO2019212427A3
WO2019212427A3 PCT/TR2018/000131 TR2018000131W WO2019212427A3 WO 2019212427 A3 WO2019212427 A3 WO 2019212427A3 TR 2018000131 W TR2018000131 W TR 2018000131W WO 2019212427 A3 WO2019212427 A3 WO 2019212427A3
Authority
WO
WIPO (PCT)
Prior art keywords
erdosteine
ascorbic acid
compositions
expectoration
cough
Prior art date
Application number
PCT/TR2018/000131
Other languages
English (en)
Other versions
WO2019212427A2 (fr
Inventor
Mahmut Bi̇lgi̇ç
Original Assignee
Neutec Ar-Ge Sanayi Ve Ticaret Anonim Şirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Ar-Ge Sanayi Ve Ticaret Anonim Şirketi filed Critical Neutec Ar-Ge Sanayi Ve Ticaret Anonim Şirketi
Publication of WO2019212427A2 publication Critical patent/WO2019212427A2/fr
Publication of WO2019212427A3 publication Critical patent/WO2019212427A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant de l'erdostéine et de l'acide ascorbique à utiliser dans le traitement de l'expectoration et de la toux.
PCT/TR2018/000131 2017-12-30 2018-12-28 Compositions comprenant de l'erdostéine et de l'acide ascorbique WO2019212427A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/23198 2017-12-30
TR2017/23198A TR201723198A2 (tr) 2017-12-30 2017-12-30 Erdostein ve askorbik asit ihtiva eden kompozisyonlar.

Publications (2)

Publication Number Publication Date
WO2019212427A2 WO2019212427A2 (fr) 2019-11-07
WO2019212427A3 true WO2019212427A3 (fr) 2019-11-28

Family

ID=67900535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/000131 WO2019212427A2 (fr) 2017-12-30 2018-12-28 Compositions comprenant de l'erdostéine et de l'acide ascorbique

Country Status (2)

Country Link
TR (1) TR201723198A2 (fr)
WO (1) WO2019212427A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035452A1 (fr) * 1995-05-10 1996-11-14 Adcock Ingram Limited Composition pharmaceutique contenant de l'acetylcysteine, de la carbocysteine ou de l'erdosteine en association avec un beta 2 agoniste et un expectorant pour le traitement des affections des voies respiratoires
US20020004078A1 (en) * 2000-02-23 2002-01-10 Daniel Gelber Composition and method for treating the effects of diseases and maladies
CA2731454A1 (fr) * 2011-02-10 2012-08-10 Russell Leblanc Composition a base de plantes medicinales et de vitamine c utilisee pour le traitement de l'inflammation et le maintien de la sante
WO2013144976A2 (fr) * 2012-03-28 2013-10-03 Medreich Limited Forme galénique de capsule de gélatine molle à mâcher d'agents mucolytiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035452A1 (fr) * 1995-05-10 1996-11-14 Adcock Ingram Limited Composition pharmaceutique contenant de l'acetylcysteine, de la carbocysteine ou de l'erdosteine en association avec un beta 2 agoniste et un expectorant pour le traitement des affections des voies respiratoires
US20020004078A1 (en) * 2000-02-23 2002-01-10 Daniel Gelber Composition and method for treating the effects of diseases and maladies
CA2731454A1 (fr) * 2011-02-10 2012-08-10 Russell Leblanc Composition a base de plantes medicinales et de vitamine c utilisee pour le traitement de l'inflammation et le maintien de la sante
WO2013144976A2 (fr) * 2012-03-28 2013-10-03 Medreich Limited Forme galénique de capsule de gélatine molle à mâcher d'agents mucolytiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAZZANI, G. ET AL.: "In vitro protection by erdosteine against oxidative inactivation of alpha-1-antitrypsin by cigarette smoke", RESPIRATION, vol. 55, no. 2, 1989, pages 113 - 118 *
SIRMALI, M. ET AL.: "Protective effects of erdosteine and vitamins C and E combination on ischemia-reperfusion- induced lung oxidative stress and plasma copper and zinc levels in a rat hind limb model", BIOLOGICAL TRACE ELEMENT RESEARCH, vol. 118, no. 1, 22 May 2007 (2007-05-22) - July 2007 (2007-07-01), pages 43 - 52, XP055657905 *

Also Published As

Publication number Publication date
TR201723198A2 (tr) 2019-07-22
WO2019212427A2 (fr) 2019-11-07

Similar Documents

Publication Publication Date Title
EP4230623A3 (fr) Composés de pyridine en tant qu'inhibiteurs allostériques de shp2
EP3173092A3 (fr) Composition contenant un arn pour le traitement de maladies tumorales
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
EP3735976A3 (fr) Utilisation thérapeutique de mitochondries et d'agents mitochondriaux combinés
WO2019032662A8 (fr) Agents de liaison à clec9a et utilisations associées
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
WO2016060996A3 (fr) Compositions d'interleukine-15 et leurs utilisations
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
WO2016190683A8 (fr) Composition pour la prévention et le traitement de maladies musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de platycodon grandiflorum
EP3710036A4 (fr) Compositions d'acide ascorbique stables et leurs procédés d'utilisation
WO2014141210A3 (fr) Cellules souches de pulpe dentaire immatures multifonctionnelles et applications thérapeutiques
WO2017022962A8 (fr) Composition pour la prévention ou le traitement d'une maladie immunitaire, comprenant un inhibiteur de la rip kinase en tant que principe actif
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
EP4272832A3 (fr) Composés antimicrobiens, compositions et leurs utilisations
CA2929436C (fr) Composes, composition pharmaceutique et methodes a utiliser dans le traitement de maladies inflammatoires
PH12017500706A1 (en) Composition containing extract or fraction of genus justicia plant
MX2018013742A (es) Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
MD3482754T2 (ro) Compoziții farmaceutice și utilizări direcționate spre tulburări de stocare lizozomale
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
CR20190131A (es) 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
PH12020550252A1 (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18917426

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18917426

Country of ref document: EP

Kind code of ref document: A2